Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab

Lung cancer is a leading cause of cancer-related deaths worldwide [1]. Approximately 85% of patients with lung cancer are diagnosed with non-small cell lung cancer (NSCLC). Because two-thirds of the patients show local advancement or have metastatic tumors at diagnosis, chemotherapy is the major strategy for the treatment of lung cancer. Molecular targeted therapies for the treatment of lung cancer have developed remarkably in the past two decades and therapies that target driver mutations, such as EGFR mutations and ALK protein fusions, are the major treatment strategies for patients with NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research